Treatment of higher-risk myelodysplastic syndromes

Bilal K. Siddiqui, Muhammad A. Jadoon, Hamid Sayar

Research output: Chapter in Book/Report/Conference proceedingChapter


The term higher-risk is used arbitrarily in clinical practice to indicate more advanced stages of myelodysplastic syndromes (MDS). The intermediate-1 and high risk groups under the International Prognostic Scoring System (IPSS) are typically considered as higher-risk disease; while with the revised IPSS (IPSS-R), the high and very high risk groups would be under the category of higher-risk disease. Treatments considered for this group of patients are usually different to, and more aggressive than those offered for the lower-risk disease. In addition, sometimes under specific circumstances, patients with lower-risk disease are treated with such aggressive therapies. This chapter will provide a comprehensive review of management strategies for higher-risk MDS. A discussion regarding logical consideration of more aggressive therapies in lower-risk disease as well as choice of therapy in higher-risk patients will be offered. The chapter will also review clinically relevant details of agents and regimens used in the treatment of higher-risk MDS. Moreover, extensive description of clinical trials and available data on specific agents used in this setting will be provided.

Original languageEnglish (US)
Title of host publicationMyelodysplastic Syndromes
Subtitle of host publicationFrom Pathogenesis to Diagnosis and Therapy
PublisherNova Science Publishers, Inc.
Number of pages28
ISBN (Print)9781624175749
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of higher-risk myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Siddiqui, B. K., Jadoon, M. A., & Sayar, H. (2013). Treatment of higher-risk myelodysplastic syndromes. In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy (pp. 247-274). Nova Science Publishers, Inc..